08-29-2011: Thermo Fisher Scientific Inc. reported that it has completed its previously announced acquisition of Phadia. Based in Uppsala, Sweden, Phadia has approximately 1,500 employees globally and had 2010 revenue of €367 million (or approximately $525 million). Phadia will become part of Thermo Fisher’s Specialty Diagnostics business.

“We are pleased to complete the acquisition of Phadia, which significantly enhances our presence in high-growth specialty diagnostics markets by adding leading allergy and autoimmunity diagnostic tests,” said Marc N. Casper, president and chief executive officer of Thermo Fisher. “Phadia provides us with growth opportunities in an under-penetrated U.S. market and allows us to leverage our strong presence in emerging geographic markets. We are delighted to welcome Phadia’s employees to our team and look forward to working together to expand our depth of capabilities for our customers who are focused on improving healthcare through better diagnostics.”

Phadia is expected to contribute $0.07 to Thermo Fisher’s 2011 full year adjusted earnings per share (EPS). This is a $0.01 increase over the original estimate of $0.06, reflecting more favorable financing rates that will primarily benefit fourth quarter results. Due to the $0.07 impact of Phadia, Thermo Fisher is raising its 2011 full year adjusted EPS guidance to a new range of $4.15 to $4.25, which would result in 20% to 23% EPS growth over 2010. In addition, Phadia is expected to add $190 million to Thermo Fisher’s 2011 revenue results. Therefore, the company is also raising its 2011 revenue guidance to a new range of $11.79 billion to $11.89 billion, for approximately 12% revenue growth over 2010.

Contact / Request information

Request further information free of charge:

Facts, background information, dossiers
More about Thermo Fisher Scientific
More about Phadia
  • News

    Thermo Fisher Scientific Completes Acquisition of Phadia

    Thermo Fisher Scientific Inc. reported that it has completed its previously announced acquisition of Phadia. Based in Uppsala, Sweden, Phadia has approximately 1,500 employees globally and had 2010 revenue of €367 million (or approximately $525 million). Phadia will become part of Thermo Fi ... more

    New POC allergy test has been cleared by FDA

    The US medical agency FDA has granted Phadia the clearance to sell and market its new POC allergy test ImmunoCAP® Rapid product in US. “This is a historical event in the diagnostic industry since it is the first semi-quantitative POC allergy test that has been FDA cleared. It is a major mi ... more

  • Companies

    Phadia GmbH

    more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE